loading...| Preferred Name | cenersen | |
| Synonyms |
EL625 OL(1)p53 Aezea® |
|
| Definitions |
A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C37454" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C37454" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000354249 |
|
| altLabel |
EL625 OL(1)p53 Aezea® |
|
| Component of | ||
| cui |
C0700610 C1328177 C3896723 C3490398 |
|
| DATE FIRST PUBLISHED |
2004-01-23 |
|
| Date last modified |
2014-09-22 |
|
| definition |
A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C37454" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C37454" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C37454 |
|
| notation |
CDR0000354249 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
cenersen |
|
| tui |
T114 T121 |